Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Biocept, Inc. (announced today the commercial availability of its new liquid biopsy test for progesterone receptor (PR), which can be used for the detection and monitoring of a key biomarker in the blood of patients with breast cancer.

Senior Vice President and Medical Director of Biocept Veena Singh, M.D. said, “The ability to detect PR expression in circulating tumor cells (CTCs) complements Biocept’s existing ER and HER2 assays for biomarker analysis in breast cancer.” He added, “With the addition of PR detection using our high sensitivity CTC platform, we offers liquid biopsy assays for all NCCN Guideline®-based biomarkers pertinent to the care of patients with breast cancer.”

President and Chief Executive Officer of Biocept, Michael Nall added, “We now have 14 commercially available liquid biopsy assays as we execute on our initiative to expand our product menu of non-invasive, cost-effective biomarker tests.”  Nall concluded, “Our goal is to offer tests to detect and track all clinically actionable biomarkers listed in the NCCN Guidelines® for solid tumors, which we believe is a compelling value proposition for Biocept in the liquid biopsy market.”

Biocept’s Target Selector™ PR expression test is performed on CTCs utilizing fluorescently labeled antibodies. The Company’s liquid biopsy tests are performed in its CLIA-certified, CAP-accredited laboratory located in San Diego, California.

About Progesterone Receptor (PR)
The progesterone receptor (PR) is a protein found inside cells. Upon binding of the steroid hormone progesterone, PR enters the nucleus and binds to DNA, leading to the production of specific proteins. Clinically, breast cancer cells can be tested for hormone sensitivity, also referred as hormone receptor status, where tumor cells that stain positive for PR and/or estrogen receptor (ER) suggest that the patient may respond to a targeted therapy.  About 80% of breast cancers are hormone receptor positive.

About NCCN Guidelines®
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research and education, is dedicated to improving the quality, effectiveness and efficiency of cancer care so that patients can live better lives.  NCCN offers a number of programs to give clinicians access to tools and knowledge that can help guide decision-making in the management of cancer. Over the past 25 years, NCCN has developed an integrated suite of tools to improve the quality of cancer care.  The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.